On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdayMar 18, 2021 11:08 am

NetworkNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Chief Risk Officer, General Counsel Transitions to Special Advisor to the Board

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in the United States, has announced that Jennifer Tung, currently serving as both chief risk officer and general counsel, for the company will be leaving her roles although she will remain a special advisor to the Board of Directors. Tung joined PLUS in September 2018 and since that time has been a central figure in assisting the company navigate the legal cannabis industry’s regulatory requirements, guidelines and processes. She also played a key role as the company announced and completed its initial public offering as well as offering invaluable…

Continue Reading

ThursdayMar 18, 2021 10:36 am

NetworkNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Launches Probulin Probiotics in China Through World’s Largest Cross-Border Marketplace

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, through its wholly owned subsidiary Probulin Probiotics LLC, is offering products in China. The products are available on Alibaba Group Holding’s Tmall (“Tmall”) Global, the world’s largest cross-border online marketplace, with a reach of more than 750 million potential customers in China, Hong Kong, Macau and Taiwan. Calling the move a tremendous opportunity, the company plans to begin shipping product next week, with products available for purchase beginning March 29, 2021. The company anticipates having its Total Care…

Continue Reading

ThursdayMar 18, 2021 10:26 am

NetworkNewsBreaks – The Movie Studio Inc. (MVES) Leverages Blockchain for Licensing of ‘Night of the Demons’ in Spain

The Movie Studio (OTC: MVES), a vertically integrated motion picture production and distribution company with completed motion picture and production assets, today announced the licensing of its 60%-owned membership of the motion picture “Night of the Demons,” starring Shannon Elizabeth, Edward Furlong and Monika Keena, for the territory of Spain, which has a combined population of 47 million. According to the update, the licensing will remain in effect through 2027. “Establishing worldwide distribution agreements for our current library of new and aggregated revenue-shared titles through our blockchain application is a fundamental cornerstone of our proposed reverse engineering of future revenue-share…

Continue Reading

ThursdayMar 18, 2021 10:03 am

NetworkNewsBreaks – Net Element Inc. (NASDAQ: NETE), Mullen Set to Move the World in Memphis

Net Element (NASDAQ: NETE) is in the process of transforming its business model to become a pure-play electric vehicle ("EV") manufacturer through a pending stock-for-stock reverse merger with privately-held Mullen Technologies Inc. Mullen today announced its intent to execute a long-term lease on an 820,000-square-foot facility located in Memphis, Tennessee. According to the update, Mullen, with the help of local and state incentives from the city of Memphis and the state of Tennessee, plans to create up to 800 jobs and deliver 100,000 vehicles over a five-year period, commencing in Q4 of 2023. Mullen’s 2P 6 SUV crossover (formerly MX-05)…

Continue Reading

ThursdayMar 18, 2021 9:50 am

NetworkNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Receives European Approval for 25 Minute COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH ("3a"), has received European approval of its point-of-care SARS-CoV-2 RT-PCR test system, called Covid-ID Lab. Covid-ID Lab is now registered as a commercial in vitro diagnostic (CE-IVD) test in Europe, and plans are in place to launch the product in Europe in April 2021. XPhyto is exploring options with various potential distribution and wholesale partners as well as potential licensees. The test offers high sensitivity, high specificity, and high robustness,…

Continue Reading

ThursdayMar 18, 2021 9:22 am

NetworkNewsBreaks – KalVista Pharmaceuticals Inc. (NASDAQ: KALV) Closes on Public Offering

KalVista Pharmaceuticals (NASDAQ: KALV), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that it has closed on upsized underwritten public offering. The offering consisted of 6,181,250 shares of its common stock; an additional 806,250 shares were included in the offering, which were sold in accordance with the full exercise of the over-allotment option granted to underwriters. The shares were sold for $36 per share, with the offering ultimately resulting in an estimated $222.5 million in gross proceeds for KalVista. According to the announcement, Roth Capital Partners acted as co-manager for the…

Continue Reading

WednesdayMar 17, 2021 3:20 pm

NetworkNewsBreaks – VPR Brands LP (VPRB) Secures Utility Patent for Revolutionary Lighter Design

VPR Brands (OTC: VPRB) is a market leader and pioneer in electronic cigarettes and vaporizers for nicotine, cannabis and cannabidiol (“CBD”), as well as other accessories such as lighters. The company owns intellectual property, including one of the original patents filed for electronic cigarette technology, and has announced that it recently received a utility patent for its new inverted lighter. “I believe what makes an iconic lighter is being able to tell what brand it is from 10 feet away; our Dissim is one of those,” said Dan Hoff, COO of VPR Brands. “In this case, the aesthetic design is…

Continue Reading

WednesdayMar 17, 2021 2:58 pm

NetworkNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces Filing of Reg A with the SEC

Healthtech Solutions (OTC: HLTT), parent company of Medi-Scan Inc. and RevHeart Inc., today announced that it filed a Reg A with the Securities and Exchange Commission on Monday, March 8, 2021, to raise up to $75 million. According to the update, the company is offering up to a maximum of 1,500,000 shares of Series B preferred stock, $0.001 par value (“Preferred Stock”), at an offering price of $50 per share. The price will remain fixed for the duration of the Offering (the “Offered Shares”). The Offering will enable Healthtech Solutions to implement its three-pronged growth plan, which includes: the creation…

Continue Reading

WednesdayMar 17, 2021 2:36 pm

NetworkNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Announces Completion of Uranium Purchases, Additional Funding

Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company, has secured 800,000 pounds of additional U.S.-warehoused uranium; the shipment is comprised of a delivery in April consisting of 500,000 pounds and a second delivery scheduled for December consisting of 300,000 pounds; this uranium purchase follows a previously announced acquisition of 400,000 pounds. In total, UEC now has contracts to purchase 1,200,000 pounds of U3O8 at a volume-weighted average price of $28.94 per pound. In addition, the company has entered into definitive agreements with institutional investors to purchase 10,000,000 UEC common shares at $3.05 per share. The registered direct offering, which…

Continue Reading

WednesdayMar 17, 2021 1:24 pm

NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In addition, two to three more clinical sites will be selected for the trial, “A Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica.” “We have selected five U.S. sites to evaluate this…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217